SCHEMBL3291302

SCHEMBL3291302

CCOC(=O)c1cn(-c2ccccc2)c2nc(NCCOC)ncc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 9/20 0.49
RAB9A P51151 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 2/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
MAPK1 P28482 1/20 0.42
PDE4A P27815 1/20 0.42
KCNH2 Q12809 1/20 0.42
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3293205 0.95 CSF1R (0.52) CSF1RRAB9ANPSR1ALDH1A1KDM4E
SCHEMBL3291981 0.88 CSF1R (0.58) CSF1RPDE4AKCNH2AXLTYRO3
SCHEMBL3293704 0.88 CSF1R (0.53) CSF1RALDH1A1MEN1KMT2ATSHR
SCHEMBL28526527 0.88 NPSR1 (0.60) CSF1RRAB9ANPSR1ALDH1A1KDM4E
SCHEMBL3289961 0.87 POLB (0.49) CSF1RRAB9ANPSR1ALDH1A1KDM4E
SCHEMBL3291781 0.86 MAPT (0.49) CSF1RRAB9ANPSR1ALDH1A1KDM4E
SCHEMBL3291092 0.86 CSF1R (0.54) CSF1RRAB9ANPSR1ALDH1A1KDM4E
SCHEMBL3292279 0.85 CSF1R (0.53) CSF1RRAB9ANPSR1ALDH1A1KDM4E
SCHEMBL28537798 0.85 CSF1R (0.62) CSF1RNPC1
SCHEMBL3291594 0.85 CSF1R (0.70) CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728003-B2 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-06-01 US disclosed
EP-1945637-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-23 EP disclosed
WO-2007033137-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060578-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR CSF1R 598/4885RAB9A 2982/4885NPSR1 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.